GH Research PLC (NASDAQ:GHRS - Get Free Report)'s stock price traded up 0.2% during mid-day trading on Thursday . The stock traded as high as $9.70 and last traded at $9.26. 22,329 shares changed hands during mid-day trading, a decline of 72% from the average session volume of 78,940 shares. The stock had previously closed at $9.24.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on GHRS shares. HC Wainwright restated a "buy" rating and issued a $40.00 price target on shares of GH Research in a research note on Thursday, September 5th. JMP Securities reiterated a "market outperform" rating and issued a $39.00 price target on shares of GH Research in a research note on Wednesday, September 4th.
Check Out Our Latest Research Report on GHRS
GH Research Trading Down 4.2 %
The company has a market capitalization of $460.47 million, a price-to-earnings ratio of -13.82 and a beta of 0.74. The firm's 50-day moving average price is $7.74 and its 200 day moving average price is $10.39.
GH Research (NASDAQ:GHRS - Get Free Report) last issued its earnings results on Tuesday, September 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.03. As a group, equities research analysts anticipate that GH Research PLC will post -0.85 earnings per share for the current fiscal year.
Institutional Trading of GH Research
An institutional investor recently raised its position in GH Research stock. Lynx1 Capital Management LP boosted its stake in GH Research PLC (NASDAQ:GHRS - Free Report) by 80.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,310,563 shares of the company's stock after acquiring an additional 1,471,946 shares during the period. GH Research accounts for 9.1% of Lynx1 Capital Management LP's investment portfolio, making the stock its 6th largest holding. Lynx1 Capital Management LP owned about 6.36% of GH Research worth $35,291,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 56.90% of the stock is owned by institutional investors and hedge funds.
About GH Research
(
Get Free Report)
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider GH Research, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GH Research wasn't on the list.
While GH Research currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
